Monday, August 29, 2016

Oramed hopes to start Phase 3 oral insulin trial next year

Oramed hopes to start Phase 3 oral insulin trial next year

August 23, 2016 by · Leave a Comment 

Tweet After posting positive Phase 2b results with its oral insulin drug candidate, ORMD-0801 in Type 2 diabetes, Oramed Pharmaceuticals (NASDAQ:ORMP) hopes to meet with the FDA before the end of 2016 to discuss proceeding with a Phase 3 clinical trial in 2017. “We believe that our data set shows that oral insulin works, which […]

In conversation with Ben Haynor

In conversation with Ben Haynor

August 16, 2016 by · Leave a Comment 

Tweet As a senior research analyst with Feltl & Co. for the past six years, Ben Haynor ranked second in the May 2013 Wall Street Journal Best on the Street publication in the Medical Equipment and Supplies category and was named the top stock picker in U.S. Health Care Equipment and Supplies in StarMine’s 2013 […]

Roth ups CymaBay price target to $6

Roth ups CymaBay price target to $6

August 12, 2016 by · Leave a Comment 

Tweet Roth Capital Partners raised its price target for CymaBay Therapeutics (NASDAQ:CBAY) to $6 from $4, citing a potential partnership for the company’s gout product. The stock closed at $1.79 on Thursday. “Following conversations with management, we are more confident that CymaBay could ink a partnership for arhalofenate (gout) in the coming six-to-12 months,” writes […]

Maxim cuts Omeros price target to $19

Maxim cuts Omeros price target to $19

August 10, 2016 by · Leave a Comment 

Tweet Maxim Group lowered its price target for Omeros (NASDAQ:OMER) to $19 from $30, citing a higher risk value from its three valuation models. The stock closed at $13.38 on Tuesday. Analyst Jason Kolbert writes that sales of the company’s Omidria are showing good traction, and “we are hopeful about seeing U.S. revenues build over […]

Maxim cuts Galena Biopharma price target to $1

Maxim cuts Galena Biopharma price target to $1

August 10, 2016 by · Leave a Comment 

Tweet Maxim Group lowered its price target for Galena Biopharma (NASDAQ:GALE) to $1 from $2, citing a shift in the company’s pipeline focus. The stock closed at 46 cents on Tuesday. At the end of June, an Independent Data Monitoring Committee stopped a Phase 3 trial of Galena’s NeuVax in early-stage breast cancer for futility. […]

IntelGenx sells Forfivo XL royalty

IntelGenx sells Forfivo XL royalty

August 6, 2016 by · Leave a Comment 

Tweet IntelGenx (OTCQX:IGXT; TSX-V:IGX) has sold its royalty on future sales of Forfivo XL to SWK Holdings for $6-million. Forfivo XL (bupropion extended release) is the first 450-milligram bupropion hydrogen chloride tablet indicated for major depressive disorder approved by the FDA. Patent protection for Forfivo XL in the U.S. expires in 2027, with an authorized […]

WB cuts Synthetic Biologics price target

WB cuts Synthetic Biologics price target

August 4, 2016 by · Leave a Comment 

Tweet William Blair lowered its price target for Synthetic Biologics (NYSE:SYN) to $7 from $10, citing potential delays to commercialize the company’s two programs. The stock closed at $1.67 on Wednesday. “We maintain our ‘outperform’ rating as we believe the fundamentals remain strong,” writes analyst Katherine Xu. “Meanwhile, the financing overhang will keep pressure on […]

Galectin completes patient recruitment in NASH trial

Galectin completes patient recruitment in NASH trial

August 3, 2016 by · Leave a Comment 

Tweet Galectin Therapeutics (NASDAQ:GALT) has completed patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis, the NASH-CX trial. The company expects to report the topline results of the trial in December 2017. “We are pleased that patient recruitment in our NASH-CX trial was completed ahead of our […]

Titan’s Probuphine gains media attention in NYC

Titan’s Probuphine gains media attention in NYC

August 1, 2016 by · Leave a Comment 

Tweet New York’s WPIX-TV has produced a segment about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine as a new treatment in the battle against heroin and prescription painkiller addiction. The FDA approved Probuphine in May to help ease opioid cravings. The WPIX feature includes a medical opinion from Dr. Richard Rosenthal, a researcher at Mount […]

Spartan announces first applications for Cube

Spartan announces first applications for Cube

August 1, 2016 by · Leave a Comment 

Tweet Closely-held Spartan Bioscience has launched the world’s smallest commercial molecular diagnostic device, the Spartan Cube, and announced its first assay applications. They are Strep A, Apolipoprotein E, a genetic mutation that increases the risk of developing Alzheimer’s disease, and Legionella, a group of bacteria that can colonize water systems such as cooling towers and […]

Next Page »

Email Newsletters with Constant Contact
Google+